Enhanced Therapeutic Efficacy of Doxorubicin for Breast Cancer Using Chitosan Oligosaccharide-Modified Halloysite Nanotubes.

Halloysite nanotubes (HNTs) are natural aluminosilicates with unique hollow lumen structure, also having high specific area, good biocompatibility, nontoxicity, and low price. Here, we designed a chitosan oligosaccharide-grafted HNTs (HNTs-g-COS) as a doxorubicin (DOX) carrier for treating breast cancer both in vitro and in vivo. The structure of HNTs-g-COS was first characterized by various methods. HNTs-g-COS showed positively charged surface and improved hemocompatibility. DOX-loaded HNTs-g-COS (DOX@HNTs-g-COS) released in cell lysate in a controlled manner. The IC50 value of DOX@HNTs-g-COS toward MCF-7 cells was 1.17 μg mL-1, while it was 2.43 μg mL-1 for free DOX. DOX@HNTs-g-COS increased the apoptosis effects of MCF-7 cells as shown in flow cytometry results. Also, reactive oxygen species of cells induced by DOX@HNTs-g-COS were drug-dose-dependent. DOX@HNTs-g-COS could enter the MCF-7 cells and induce mitochondrial damage as well as attack the nuclei. The in vivo antitumor effect of DOX@HNTs-g-COS was investigated in 4T1-bearing mice. The tumor-inhibition ratio of DOX@HNTs-g-COS was 83.5%, while it was 46.1% for free DOX. All mice treated with DOX@HNTs-g-COS survived over 60 days. DOX@HNTs-g-COS showed fewer ruptured cardiomyocytes and no obvious systemic toxicity. Therefore, the rational designed HNTs nanocarrier for chemotherapy drug showed promising applications in tumor treatment.

[1]  Jinhui Peng,et al.  Adsorption behavior of methylene blue onto waste-derived adsorbent and exhaust gases recycling , 2017 .

[2]  Jianping Zhou,et al.  Mitochondria and nuclei dual-targeted heterogeneous hydroxyapatite nanoparticles for enhancing therapeutic efficacy of doxorubicin. , 2016, Biomaterials.

[3]  Zhaoxia Jin,et al.  Does halloysite behave like an inert carrier for doxorubicin , 2016 .

[4]  Shanshan Zhu,et al.  Facile preparation of homogeneous and length controllable halloysite nanotubes by ultrasonic scission and uniform viscosity centrifugation , 2016 .

[5]  Y. Lvov,et al.  Evaluation of toxicity of nanoclays and graphene oxide in vivo: a Paramecium caudatum study , 2016 .

[6]  K. Zhong,et al.  Casp3/7-Instructed Intracellular Aggregation of Fe3O4 Nanoparticles Enhances T2 MR Imaging of Tumor Apoptosis. , 2016, Nano letters.

[7]  S. Lippard,et al.  Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer therapy. , 2016, ACS nano.

[8]  Tianfeng Chen,et al.  Functionalized halloysite nanotube by chitosan grafting for drug delivery of curcumin to achieve enhanced anticancer efficacy. , 2016, Journal of materials chemistry. B.

[9]  Tianfeng Chen,et al.  Tailoring Particle Size of Mesoporous Silica Nanosystem To Antagonize Glioblastoma and Overcome Blood-Brain Barrier. , 2016, ACS applied materials & interfaces.

[10]  David G. Evans,et al.  A layered drug nanovehicle toward targeted cancer imaging and therapy. , 2016, Journal of materials chemistry. B.

[11]  Wei Tao,et al.  Redox-Responsive Polyphosphoester-Based Micellar Nanomedicines for Overriding Chemoresistance in Breast Cancer Cells. , 2015, ACS applied materials & interfaces.

[12]  Christine Allen,et al.  The challenges facing block copolymer micelles for cancer therapy: In vivo barriers and clinical translation. , 2015, Advanced drug delivery reviews.

[13]  Tianfeng Chen,et al.  Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways. , 2015, Biomaterials.

[14]  Hong Chen,et al.  A theranostic prodrug delivery system based on Pt(IV) conjugated nano-graphene oxide with synergistic effect to enhance the therapeutic efficacy of Pt drug. , 2015, Biomaterials.

[15]  Liqun Zhang,et al.  Highly aging-resistant elastomers doped with antioxidant-loaded clay nanotubes. , 2015, ACS applied materials & interfaces.

[16]  Marco Orecchioni,et al.  Graphene as Cancer Theranostic Tool: Progress and Future Challenges , 2015, Theranostics.

[17]  Meiying Wang,et al.  Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice , 2015, ACS nano.

[18]  Wen-jie Zheng,et al.  Rational design of selenadiazole derivatives to antagonize hyperglycemia-induced drug resistance in cancer cells. , 2015, Chemistry, an Asian journal.

[19]  R. Mangues,et al.  Gated Mesoporous Silica Nanoparticles Using a Double‐Role Circular Peptide for the Controlled and Target‐Preferential Release of Doxorubicin in CXCR4‐Expresing Lymphoma Cells , 2015 .

[20]  Jianwen Luo,et al.  Nanohybrid liposomal cerasomes with good physiological stability and rapid temperature responsiveness for high intensity focused ultrasound triggered local chemotherapy of cancer. , 2015, ACS nano.

[21]  S. Milioto,et al.  Development and characterization of co-loaded curcumin/triazole-halloysite systems and evaluation of their potential anticancer activity. , 2014, International journal of pharmaceutics.

[22]  Wei Tao,et al.  Polyphosphoester-based nanoparticles with viscous flow core enhanced therapeutic efficacy by improved intracellular drug release. , 2014, ACS applied materials & interfaces.

[23]  Mingxian Liu,et al.  Recent advance in research on halloysite nanotubes-polymer nanocomposite , 2014 .

[24]  M. Portero-Otín,et al.  Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. , 2014, Biochemical pharmacology.

[25]  H. Fuchs,et al.  Cellular interactions of doxorubicin-loaded DNA-modified halloysite nanotubes. , 2013, Nanoscale.

[26]  I. Chourpa,et al.  Recent advances in theranostic nanocarriers of doxorubicin based on iron oxide and gold nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[27]  Yuri Lvov,et al.  Halloysite clay nanotubes as a ceramic "skeleton" for functional biopolymer composites with sustained drug release. , 2013, Journal of materials chemistry. B.

[28]  Changren Zhou,et al.  Chitosan-halloysite nanotubes nanocomposite scaffolds for tissue engineering. , 2013, Journal of materials chemistry. B.

[29]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[30]  Xinge Zhang,et al.  Glycopolymer micelles with reducible ionic cores for hepatocytes-targeting delivery of DOX. , 2013, International journal of pharmaceutics.

[31]  H. Otsuka,et al.  Internally Modified Halloysite Nanotubes as Inorganic Nanocontainers for a Flame Retardant , 2013 .

[32]  Mingxian Liu,et al.  Chitosan/halloysite nanotubes bionanocomposites: structure, mechanical properties and biocompatibility. , 2012, International journal of biological macromolecules.

[33]  Q. Mei,et al.  In Vitro and In Vivo Antitumor Activity of a Novel pH-Activated Polymeric Drug Delivery System for Doxorubicin , 2012, PloS one.

[34]  Zongwen Liu,et al.  Organosilane functionalization of halloysite nanotubes for enhanced loading and controlled release , 2012, Nanotechnology.

[35]  Hoik Lee,et al.  Aggregation and Stabilization of Carboxylic Acid Functionalized Halloysite Nanotubes (HNT-COOH) , 2012 .

[36]  Daniel A. Heller,et al.  Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.

[37]  Hao Hong,et al.  cRGD-functionalized, DOX-conjugated, and ⁶⁴Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. , 2011, Biomaterials.

[38]  Jin-dun Liu,et al.  Immobilization of enzyme biocatalyst on natural halloysite nanotubes , 2010 .

[39]  Mingwu Shen,et al.  Electrospun poly(lactic-co-glycolic acid)/halloysite nanotube composite nanofibers for drug encapsulation and sustained release , 2010 .

[40]  Zhang Xiang,et al.  Rapid adsorption of Cr (VI) on modified halloysite nanotubes , 2010 .

[41]  R. Hamanaka,et al.  Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. , 2010, Trends in biochemical sciences.

[42]  Y. Lvov,et al.  Clay nanotubes for corrosion inhibitor encapsulation: release control with end stoppers , 2010 .

[43]  V. Vergaro,et al.  Cytocompatibility and uptake of halloysite clay nanotubes. , 2010, Biomacromolecules.

[44]  X. Qu,et al.  Knocking-Down Cyclin A2 by siRNA Suppresses Apoptosis and Switches Differentiation Pathways in K562 Cells upon Administration with Doxorubicin , 2009, PloS one.

[45]  Yuri Lvov,et al.  Halloysite tubes as nanocontainers for anticorrosion coating with benzotriazole. , 2009, ACS applied materials & interfaces.

[46]  Vladimir Torchilin,et al.  Organized shells on clay nanotubes for controlled release of macromolecules. , 2009, Macromolecular rapid communications.

[47]  Cuiping Li,et al.  Polymer‐modified halloysite composite nanotubes , 2008 .

[48]  Zongwen Liu,et al.  Functionalization of Halloysite Clay Nanotubes by Grafting with γ-Aminopropyltriethoxysilane , 2008 .

[49]  Peng Liu,et al.  Adsorption behavior of methylene blue on halloysite nanotubes , 2008 .

[50]  H. Möhwald,et al.  Halloysite clay nanotubes for controlled release of protective agents. , 2008, ACS nano.

[51]  Peng Liu,et al.  Halloysite nanotubes grafted hyperbranched (co)polymers via surface-initiated self-condensing vinyl (co)polymerization , 2008 .

[52]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[53]  B. Guo,et al.  Properties of halloysite nanotube–epoxy resin hybrids and the interfacial reactions in the systems , 2007 .

[54]  S. Pieczenik,et al.  Mitochondrial dysfunction and molecular pathways of disease. , 2007, Experimental and molecular pathology.

[55]  S. Ferrari,et al.  Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma , 2007, Anti-cancer drugs.

[56]  Nalinkanth G. Veerabadran,et al.  CLAY NANOTUBES FOR ENCAPSULATION AND SUSTAINED RELEASE OF DRUGS , 2007 .

[57]  M. Prato,et al.  Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type. , 2007, Nature nanotechnology.

[58]  Michael S. Goldberg,et al.  Nanostructured materials for applications in drug delivery and tissue engineering , 2007, Journal of biomaterials science. Polymer edition.

[59]  Bruno Delvaux,et al.  Halloysite clay minerals – a review , 2005, Clay Minerals.

[60]  Y. Nodasaka,et al.  Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo. , 2005, Molecular bioSystems.

[61]  B. Queenan,et al.  Programmed cell death via mitochondria: Different modes of dying , 2005, Biochemistry (Moscow).

[62]  D. L. Le Couteur,et al.  The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[63]  Joy Joseph,et al.  Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms , 2004, Journal of Biological Chemistry.

[64]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[65]  R. Tharanathan,et al.  Low molecular weight chitosans: preparation with the aid of papain and characterization. , 2004, Biochimica et biophysica acta.

[66]  R. Frost,et al.  Intercalation of Halloysite: A Raman Spectroscopic Study , 1997 .

[67]  Nicholas A. Peppas,et al.  A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs , 1987 .

[68]  L. Du,et al.  In vitro hemocompatibility and cytotoxicity evaluation of halloysite nanotubes for biomedical application , 2015 .

[69]  Yi Yan Yang,et al.  Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. , 2014, Biomaterials.

[70]  Nengqin Jia,et al.  Functionalized halloysite nanotube-based carrier for intracellular delivery of antisense oligonucleotides , 2011, Nanoscale research letters.

[71]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.